Search Results

You are looking at 31 - 40 of 151 items for :

  • "renal cell carcinoma" x
Clear All
Full access

Daniel Y. C. Heng and Toni K. Choueiri

References 1 Cohen HT McGovern FJ . Renal-cell carcinoma . N Engl J Med 2005 ; 353 : 2477 – 2490 . 2 Kovacs G Akhtar M Beckwith BJ . The Heidelberg classification of renal cell tumours . J Pathol 1997 ; 183 : 131 – 133

Full access

Toni K. Choueiri

carcinoma receiving vascular endothelial growth factor targeted therapy . J Urol 2011 ; 185 : 60 – 66 . 2. Manola J Royston P Elson P . Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang and Richard B. Wilder

. Participation in clinical trials is especially encouraged. Overview An estimated 58,240 Americans were diagnosed with renal cancer and 13,040 died of the disease in the United States in 2010. 1 Renal cell carcinoma (RCC) constitutes 2% to 3% of all

Full access

Eric Jonasch

“It has been an exciting 15 years for renal cell carcinoma,” noted Eric Jonasch, MD, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, and Director of the Von Hippel–Lindau Clinical Center at The

Full access

Saby George, Roberto Pili, Michael A. Carducci and Jenny J. Kim

inhibitors. Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer and Rashmi Kumar

. Overview Renal cell carcinoma (RCC) constitutes approximately 3.9% of new cancers, with a median age of 64 years at diagnosis. The American Cancer Society estimated that 63,920 Americans would be diagnosed with and 13,860 would die of RCC in the United

Full access

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, Shawna Boyle, Maria I. Carlo, Brandon Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Christos Kyriakopoulos, Elaine T. Lam, Clayton Lau, Bryan Lewis, David C. Madoff, Brittany McCreery, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M. Pierorazio, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Bradley Somer, Jeffrey Sosman, Mary A. Dwyer and Angela D. Motter

option for patients in both the favorable and poor/intermediate International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups. For the same update, the panel also discussed whether axitinib/pembrolizumab might be used in clinical

Full access

Senthil Damodaran, Ewa Mrozek, David Liebner and Kari Kendra

: 3122 – 3131 . 10 White RL Jr Schwartzentruber DJ Guleria A . Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma . Cancer 1994 ; 74 : 3212

Full access

Anthony J. Olszanski

cancer,” he added. In the 21st century, the first cancer vaccine was approved worldwide in Russia for renal cell carcinoma in 2008. In fairly rapid succession, sipuleucel-T was approved for prostate cancer, the CTLA-4 inhibitor ipilimumab was approved

Full access

Somasundaram Subramaniam, Jason A. Zell and Pamela L. Kunz

, everolimus inhibits expression of hypoxia-inducible factor and reduces vascular endothelial growth factor (VEGF) expression. Everolimus was initially approved by the FDA in 2009 for the second-line treatment of advanced renal cell carcinoma. Subsequently